Navigation Links
DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI)
Date:7/29/2010

Saliva-Based DNA Collection Product Chosen for Study to Identify Host Correlates of Protection Against Tuberculosis

OTTAWA, July 29 /PRNewswire/ - DNA Genotek, a leading provider of products for biological sample collection, stabilization and preparation, today announced that the world's leading TB vaccine research site, the South African Tuberculosis Vaccine Initiative (SATVI), has chosen Oragene-DNA for a study aimed at identifying host correlates of protection against TB, following BCG vaccination.

This study is looking at the genetic differences between infants who are either protected or not protected against TB, following BCG vaccination. The researchers are also interested in determining if there is a genetic predisposition to susceptibility of TB by recruiting parents of both protected and unprotected infants. Over the course of the 4 year study, approximately 6,000 DNA samples will be collected with the Oragene-DNA Self-Collection Kits.

Oragene-DNA is an all-in-one system for the collection, stabilization, transportation and purification of DNA from saliva that enables easy, reliable and cost effective collection of samples from large numbers of individuals while providing high quality DNA. The product provides DNA sample stability at ambient temperatures, making it ideal for remote collection in sub-Saharan Africa.

Muki Shey, student researcher coordinating the study at SATVI, which is based at the University of Cape Town, is upbeat about using the product. "We believe the Oragene-DNA system is the most practical for collecting DNA in our environment. Our field site is located in a poor rural area covering an area of about 12,000 square km. TB is highly endemic in the region, which has one of the highest rates in sub-Saharan Africa. We had been utilizing blood collection for DNA but we encountered study withdrawals from some participants due to concerns over blood-based collection methods. With Oragene-DNA, we are achieving a compliance rate of 95%."

"Developing new diagnostic tools, vaccines and treatments are critical to stopping the TB epidemic," said Shuma Panse, GBC Senior Manager of Membership and Advisory Services. "By participating in this important study in South Africa, DNA Genotek is making a significant contribution to the research that is essential to developing an effective TB vaccine."

"SATVI is the largest dedicated TB vaccine research group on the African continent. By using Oragene-DNA, SATVI is achieving remarkable compliance rates from study participants, which is now enabling them to cost-effectively collect the samples they need to conduct their research into this infectious disease," said Ian Curry, president and CEO, DNA Genotek. "We are proud that Oragene-DNA's high quality and ease of use are enabling this research project to save time and money while achieving outstanding compliance rates."

About DNA Genotek:

DNA Genotek focuses on providing high-quality biological sample collection products. The company's Oragene family of products provide the best way to collect and preserve large amounts of DNA from saliva. The company also offers a family of products for collecting DNA from animals and livestock. The reliability and ease-of-use of the company's products have resulted in rapid adoption at top-tier organizations globally, including Harvard, Stanford, Cambridge, Johns Hopkins, Anthony Nolan, and the Institut Gustave Roussy. DNA Genotek markets its products worldwide and has established a global customer base in over 100 countries. For more information about DNA Genotek, visit www.dnagenotek.com

About SATVI

The South African Tuberculosis Vaccine Initiative was established in 2001. It is located within the prestigious Institute of Infectious Disease and Molecular Medicine of the University of Cape Town. SATVI is the largest dedicated TB vaccine research group on the African continent and the most advanced TB vaccine research site in the world. The research team consists of a highly trained team of study clinicians, epidemiologists and immunologists who manage the research projects. Our field site is located in a poor rural area covering an area of about 12,000 square km. TB is highly endemic in the region, which has one of the highest rates in sub-Saharan Africa. For more information about the South African Tuberculosis Vaccine Initiative, please visit http://www.satvi.uct.ac.za/.

(R) Oragene is a registered trademark of DNA Genotek, Inc.


'/>"/>
SOURCE DNA Genotek Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
2. CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008
3. Premier Research Achieves Double-Digit Growth in Functional Sourcing for the Third Straight Year
4. Bioenergy D-Ribose Achieves Highest Safety Standard
5. SleepQuest Achieves Coveted Accreditation
6. Accuray Achieves Milestone of 150th CyberKnife System Installed Worldwide
7. Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate
8. Level 3 Inspection Achieves 100% Compliance in ISO 9001 & AS 9100 Certification
9. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
10. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
11. VirtualScopics Achieves Operating Cash Flow Breakeven in the Fourth Quarter 2008; Reports Record 2008 Revenue and Gross Profit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical ... it has acquired the assets of Theorem Clinical Research - Clinical Supplies ... clinical trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials ...
(Date:12/6/2016)... 6, 2016  SRI International has been awarded ... the National Institutes of Health,s National Institute of ... AIDS (NIAID-DAIDS) to support the manufacturing and characterization ... agents. Under the seven-year contract, SRI will provide ... for candidate HIV-prevention products that emerge from investigator-initiated ...
(Date:12/5/2016)... 5, 2016 Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced that data ... of Alzheimer,s disease will be presented at the 2016 ... December 9, 2016 in San Diego ... both simple and complex measures of activities of daily ...
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation of AxioMed’s exclusive ... production, company President, Jake Lubinski will be traveling to Germany on December 6th. ... Cologne and Karlsruhe to discuss the benefits of a viscoelastic total disc replacement. ...
Breaking Biology Technology:
(Date:12/6/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... of €500.0 million principal amount of its 1.414% senior unsecured ... 2.425% senior unsecured notes due 2026. The ... 2016, subject to the satisfaction of customary closing conditions.  The ... The Company intends to use the net ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
(Date:12/6/2016)... , Dec. 6, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... announced today a five (5) year funding commitment ... to expand the rehabilitation and reentry support to ... History Established in 2004, the Prison Entrepreneurship Program ...
Breaking Biology News(10 mins):